Compare Charles River Laboratories Intl. Inc (CRL) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Infosys Limited — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Infosys Limited trades at $12.4 (market cap $50.55B). The key difference: Infosys Limited is far larger — about 3.8× Charles River Laboratories Intl. Inc's market cap, and Infosys Limited pays a 4.16% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | INFY | |
|---|---|---|
Market Cap | $13.46B | $50.55B |
Sector | Health | Technology |
52-Week High | $282.00 | $20.22 |
52-Week Low | $145.57 | $10.49 |
Enterprise Value | $16.30B | $48.30B |
Dividend Yield | — | 4.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
INFY trades at $12.28, down 2.23% today, with a mixed technical picture showing bullish moving averages but overbought RSI levels. Fundamentally, the company reported Q1 2027 revenue below expectations but maintained strong margins and AI growth, with a P/E of 15.56 and robust ROE of 32.12%. Recent news includes strategic AI collaborations and a CEO transition, while analyst sentiment remains cautious with a consensus price target of $11.05.
The outlook for INFY is balanced; solid profitability and AI adoption offer upside, but near-term revenue softness and elevated valuation pose risks. Investors should weigh strong cash flow and market position against competitive pressures and execution challenges in a volatile IT services market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
